DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

EB 3/31/97

D 1286 B

Food and Drug Administration
Kansas City District Office
11630 West 80th Street
P.O. Box 15905
Lenexa, Kansas 66285-5905

Telephone: (913) 752-2100

Certified/Return Receipt Requested

March 25, 1997

WARNING LETTER

Tom Lohry, President
Kay Dee Feed Co., Inc.
1825 Grand Avenue
Sioux City, Iowa 51107

Ref. # - KAN-97-010

Dear Mr. Lohry:

An inspection of your medicated feed mill operation, located at the above address, conducted by an inspector with the Iowa Department of Agriculture on January 14 and 24, 1997, found significant deviations from Current Good Manufacturing Practice (CGMP) regulations for Medicated Feeds (21 CFR, Part 225). Such deviations cause medicated feeds being manufactured at this facility to be adulterated within the meaning of Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (Act).

Our investigation found: 1) failure to conduct annual potency assays on at least three representative samples of your free choice medicated mineral block containing Lasalocid; 2) failure to store herbicides and chemical fertilizers separately from medicated feeds; 3) failure to accurately record manufacturer's drug lot numbers; 4) failure of the daily drug inventory record to show a comparison between actual and theoretical drug usage; 5) failure to use labels with correct feeding instructions for "Royal 12 Mineral" and "Doyle Smith Custom Mix"; 6) failure of the Master Formula Records to include mixing times.

The above is not intended to be an all-inclusive list of violations. As a manufacturer of medicated and non-medicated feeds, you are responsible for assuring that your overall operation and the products you manufacture are in compliance with the law. At the conclusion of the inspection Form FDA 483, Inspectional Observations, was issued to and discussed with Marvin DeVos, Manager. This form is a comprehensive listing of deviations observed by the inspector during the inspection. A copy of this form is enclosed for your information.

DISTRIBUTION:
Orig. & Enclosure: Addressee
bcc: LF; FF(1912886); HFA-224; HFV-236; HFV-226; HFI-35/DIB(via FOI); HFC-210; RRW; SC/RP; IBRF; CRP:tlw

You should take prompt action to correct the noted violations, and you should establish procedures whereby such violations do not recur. Failure to promptly correct these violations may result in regulatory and/or administrative sanctions. These sanctions include, but are not limited to, seizure, injunction, and/or notice of opportunity for a hearing on a proposal to withdraw approval of your facility license under Section 512(m)(4)(B)(ii) of the Act and 21 CFR 514.115(c)(2). (This letter constitutes official notification under the law.) Based on the results of the January 14 and 24 inspection, evaluated together with the evidence before FDA when the license was approved, the methods used in, or the facilities and controls used for, the manufacture, processing, and packing of medicated feeds are inadequate to assure and preserve the identity, strength, quality, and purity of the new animal drugs therein. This letter notifies you of our findings and provides you an opportunity to correct the above deficiencies.

You should notify this office in writing, within fifteen (15) working days of receipt of this letter, to inform us of the specific steps you have taken to correct the noted violations and to prevent their recurrence. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. You may address your reply to Clarence R. Pendleton, Compliance Officer, at the above address.

Sincerely,

W. Michael Rogers
District Director
Kansas City District

Enclosure - Form FDA 483

cc: Marvin DeVos, Manager
Kay Dee Feed Co., Inc.
1825 Grand Avenue
Sioux City, Iowa 51107